Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Veracyte Inc. (VCYT:NASDAQ), powered by AI.
Veracyte Inc. is currently trading at $50.92. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Veracyte Inc. on Alpha Lenz.
Veracyte Inc.'s P/E ratio is 60.3.
“Veracyte Inc. trades at a P/E of 60.3 (premium valuation) with modest ROE of 5.3%. 3Y revenue CAGR of 20.4% highlights clear growth momentum.”
Ask for details →Veracyte Inc. is a genomic diagnostics company specializing in advanced molecular diagnostic tests that address critical healthcare needs. The primary function of Veracyte is to improve patient outcomes by providing more precise and less invasive diagnosis through genomic testing. This enables physicians to make better-informed treatment decisions, particularly in oncology, pulmonology, and other critical medical areas. Notable features of Veracyte's offerings include tests that reduce the need for unnecessary surgeries and procedures by providing reliable diagnostic results, thereby impacting the healthcare system by minimizing patient risk and overall healthcare costs. The company's products are largely based on proprietary genomic platforms and algorithms, driving their innovation in diagnostic accuracy. In the financial markets, Veracyte plays an essential role by offering investors exposure to the rapidly evolving field of precision medicine and genomic diagnostics. Its contributions to the healthcare sector underscore the growing demand for personalized medical solutions, reflecting broader trends towards value-based care and technological advancements in medical diagnostics.
“Veracyte Inc. trades at a P/E of 60.3 (premium valuation) with modest ROE of 5.3%. 3Y revenue CAGR of 20.4% highlights clear growth momentum.”
Ask for details →Veracyte Inc. (ticker: VCYT) is a company listed on NASDAQ in the Healthcare sector (Diagnostics & Research). It has approximately 824 employees. Market cap is $4.0B.
The current price is $50.92 with a P/E ratio of 60.31x and P/B of 3.06x.
ROE is 5.34% and operating margin is 15.14%. Annual revenue is $517M.